A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD
Launched by MACUCLEAR, INC. · Nov 12, 2009
Trial Information
Current as of June 23, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of dry AMD or;
- • Normal, healthy volunteer
- Exclusion Criteria:
- • Uncontrolled systemic disease
- • Women who are pregnant, nursing, or planning a pregnancy during the study's duration
About Macuclear, Inc.
Macuclear, Inc. is a pioneering clinical trial sponsor dedicated to advancing innovative therapies for retinal diseases and ocular health. With a strong focus on developing cutting-edge treatments, the company leverages its expertise in ophthalmology to conduct rigorous clinical trials that adhere to the highest standards of research integrity and patient safety. Committed to collaboration with leading research institutions and healthcare professionals, Macuclear strives to enhance patient outcomes and improve quality of life through the discovery and development of transformative medical solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Andover, Massachusetts, United States
Patients applied
Trial Officials
Gail L Torkildsen, M.D.
Principal Investigator
Andover Eye Associates
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials